tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Tempest Therapeutics receives ODD from EMA for amezalpat
PremiumThe FlyTempest Therapeutics receives ODD from EMA for amezalpat
2M ago
Tempest Therapeutics Reports Q1 2025 Financial Results
Premium
Company Announcements
Tempest Therapeutics Reports Q1 2025 Financial Results
2M ago
Tempest Therapeutics: Navigating Financial Challenges with Promising Clinical Data and Strategic Partnerships
Premium
Ratings
Tempest Therapeutics: Navigating Financial Challenges with Promising Clinical Data and Strategic Partnerships
2M ago
Tempest Therapeutics downgraded at Scotiabank as amezalpat finds no suitors
PremiumThe FlyTempest Therapeutics downgraded at Scotiabank as amezalpat finds no suitors
4M ago
Tempest Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
Premium
The Fly
Tempest Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
4M ago
Tempest Therapeutics downgraded to Sector Perform from Outperform at Scotiabank
Premium
The Fly
Tempest Therapeutics downgraded to Sector Perform from Outperform at Scotiabank
4M ago
Tempest Therapeutics treatment of FAP granted FDA orphan designation
PremiumThe FlyTempest Therapeutics treatment of FAP granted FDA orphan designation
4M ago
Tempest Therapeutics Advances Cancer Therapies Amid Financial Challenges
Premium
Company Announcements
Tempest Therapeutics Advances Cancer Therapies Amid Financial Challenges
4M ago
Tempest Therapeutics price target lowered to $7 from $13 at Scotiabank
Premium
The Fly
Tempest Therapeutics price target lowered to $7 from $13 at Scotiabank
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100